Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Xvivo Perfusion AB ( (SE:XVIVO) ).
XVIVO Perfusion AB has invited investors, analysts and other stakeholders to a conference call and webcast on 27 January 2026 to present its Year-end Report 2025, with CEO Christoffer Rosenblad and CFO Kristoffer Nordström leading the presentation. The year-end report will be published the same morning ahead of the call, and participants will be able to follow the event via webcast or teleconference, submit questions, and access accompanying presentation slides on the company’s website, underscoring XVIVO’s ongoing efforts to maintain active and transparent communication with the capital market.
The most recent analyst rating on (SE:XVIVO) stock is a Hold with a SEK217.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.
More about Xvivo Perfusion AB
Founded in 1998, XVIVO Perfusion AB is a Swedish medical technology company focused exclusively on extending the life of major organs to enable more successful transplants. Its solutions support clinicians and researchers in advancing transplantation medicine, and the company operates from its headquarters in Gothenburg with offices and research sites across two continents. XVIVO is listed on Nasdaq Stockholm under the ticker symbol XVIVO.
Average Trading Volume: 157,286
Technical Sentiment Signal: Sell
Current Market Cap: SEK6.39B
For an in-depth examination of XVIVO stock, go to TipRanks’ Overview page.